Alice Galli

Oct 23, 2024 | onlinelibrary.wiley.com | Andrea Pilotto |Alice Galli |Cinzia Zatti |Fabio Placidi

Introduction Identifying in vivo markers that reflect risk for phenoconversion to clinically evident alpha-synucleinopathies remains an unmet need. Alpha-synucleinopathies include a spectrum of neurodegenerative disorders characterized by neuronal loss caused by the aggregation of misfolded α-synuclein protein leading to dopaminergic deficits.

May 6, 2024 | medrxiv.org | Alessandro Padovani |Salvatore Caratozzolo |Alice Galli |Luca Crosani

The authors have declared no competing interest. This study did not receive any fundingI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Apr 3, 2024 | medrxiv.org | Micol Avenali |Alice Galli |Silvia P Caminiti |Rachele Malito

The authors report no disclosures relevant to the manuscript. Outside the submitted work, SPC is supported by #NEXTGENERATIONEU (NGEU) and funded by the Ministry of University and Research (MUR), National Recovery and Resilience Plan (NRRP), project MNESYS (PE0000006), a multiscale integrated approach to the study of the nervous system in health and disease (DN. 1553 11.10.2022). CT has received personal fees for participating in advisory boards for Eli Lilly. This study did not receive any funding.